DIRS.INFO The most relevant business & tech news

☆ Eli Lilly results top estimates on Mounjaro strength but slashes full-year profit outlook
▼ + stars: | 2023-11-02 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

Eli Lilly on Thursday reported third-quarter revenue and adjusted earnings that topped estimates on strong demand for its diabetes drug Mounjaro, but slashed its full-year profit guidance due to charges primarily related to its recent acquisitions. Eli Lilly recorded pre-tax "in-process research and development" charges of $2.98 billion, which are primarily related to a slew of recent buyouts, including DICE Therapeutics, Versanis Bio and Emergence Therapeutics AG. "This is essentially the future value of business development deals we have done," Eli Lilly CEO David Ricks said on CNBC's "Squawk Box" on Thursday. But Eli Lilly reiterated its full-year revenue forecast of between $33.4 billion and $33.9 billion. With a market cap of roughly $526 billion, Eli Lilly is the largest pharmaceutical company based in the U.S.

Persons: Eli Lilly, Jardiance, David Ricks Organizations: LSEG, Therapeutics, U.S Locations: Mounjaro, Wednesday's

☆ Eli Lilly's rally on blowout Mounjaro sales signals a new leg higher for the stock
▼ + stars: | 2023-11-02 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +8 min

LLY YTD mountain Eli Lilly's year-to-date stock performance. Investors are understandably cheering the results, sending Eli Lilly shares higher by more than 4%. "Eli Lilly today is beginning its next leg of going up," Jim Cramer said during Thursday's Morning Meeting . The most important line item was Mounjaro sales, which cleared Wall Street's high bar. Excluding that divestiture and the $387 million in Covid antibody sales in the year-ago quarter, Eli Lilly's sales grew 24% on an annual basis — a highly respectable figure.

Persons: Eli Lilly, LLY, Mounjaro, it's, Eli Lilly's, Jim Cramer, Jim, It's, Novo's, Lilly, We're, Dave Ricks, Ricks, Trulicity, Anat Ashkenazi, Lilly —, Ashkenazi, Jim Cramer's, David Ricks, Eli Lilly Scott Mlyn Organizations: Drug Administration, FDA, Novo Nordisk, CNBC, Management, Dice Therapeutics, Therapeutics Locations: North, Concord , North Carolina, U.S, Indianapolis

☆ Eli Lilly is on a buying spree. Here’s what it means for investors like us
▼ + stars: | 2023-10-05 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com time to read: +9 min

Still, he said it's "healthy" for a company like Eli Lilly — valued over $500 billion, as of Thursday — to be executing smaller deals. "They can still put their mark on an asset or a constellation of drugs," said Seigerman, who has a buy rating and $633-per-share price target on Eli Lilly stock. LLY 1Y mountain Eli Lilly's stock performance over the past 12 months. Details on the deals The three companies Eli Lilly bought this summer have drugs in various stages of the clinical development process. In the near term, though, they may result in a noisy third-quarter earnings report as Eli Lilly records the acquisitions.

Persons: Eli Lilly, Mounjaro, Jim Cramer, Eli Lilly's, Lilly, –, Verzenio, Evan Seigerman, Eli Lilly —, Seigerman, Lilly's, Dice, Versanis, Sigilon, that's, BMO's Seigerman, Eli, we'd, Jim Cramer's, Jim, Daniel Acker Organizations: Indianapolis, U.S . Food, Drug Administration, BMO Capital, Immunology, Therapeutics, Siligon Therapeutics, Oncology, Club, Department of Health, Human Services, Dice Therapeutics, Alzheimer's, Treasury, CNBC, Bloomberg, Getty

☆ Lilly eyes targeted cancer therapies with $1.4 billion Point Biopharma deal
▼ + stars: | 2023-10-03 | by ( Bhanvi Satija | Leroy | ) www.reuters.com time to read: +2 min

(Reuters) -Eli Lilly and Co will buy Point Biopharma Global for $1.4 billion, the companies said on Tuesday, gaining access to experimental therapies that enable precise targeting of cancer. Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close. Shares of Indiana-based Point Biopharma soared 85%, while Lilly’s stock was down about 3%. Point Biopharma has licensed both its late-stage experimental therapies to Lantheus Holdings since 2022. A Lantheus spokesperson said the company’s commercial rights remain intact and its collaboration with Point Biopharma is progressing in line with expectations.

Persons: Eli Lilly, Mike Segar, Lilly, ”, William Blair, Andy Hsieh Organizations: Reuters, Company, REUTERS, Dice Therapeutics, Novartis, Lantheus Holdings Locations: Branchburg , New Jersey, Indiana, Biopharma’s Indianapolis, PNT2002, U.S

☆ Exclusive: MoonLake Immunotherapeutics explores sale-sources
▼ + stars: | 2023-07-14 | by ( David Carnevali | ) www.reuters.com time to read: +2 min

July 14 (Reuters) - MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter. Immunology-focused companies have been coveted acquisition targets, as highlighted by recent deals such as Merck & Co's (MRK.N) $10.8 billion acquisition of Prometheus BioSciences Inc and Eli Lilly's (LLY.N) $2.4 billion purchase of Dice Therapeutics (DICE.O). MoonLake is testing Sonelokimab for the treatment of other inflammatory conditions, including psoriatic arthritis and psoriasis. If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG (NOVN.S) and AbbVie Inc (ABBV.N). In 2022, MoonLake went public through a merger with a special purpose acquisition company, which helped it raise more than $200 million in cash.

Persons: drugmakers, Eli Lilly's, MoonLake, hidradenitis suppurativa, hidradenitis, Merck KGaA, David Carnevali, Josie Kao Organizations: Nasdaq, Merck, Co's, Prometheus BioSciences, Dice Therapeutics, Novartis AG, AbbVie Inc, Citigroup, Thomson Locations: Zug, Switzerland, New York

☆ CNBC Daily Open: Rethinking the rally
▼ + stars: | 2023-06-21 | by ( Yeo Boon Ping | ) www.cnbc.com time to read: +2 min

This report is from today's CNBC Daily Open, our new, international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Rally haltedU.S. markets closed in the red Tuesday, halting a rally that drove stocks to their highest levels in more than a year. The UK 'doom loop'The U.K. economy is trapped in a growth "doom loop," according to the country's Institute for Public Policy Research. The International Monetary Fund expects the U.K. economy to grow 0.4% this year.

Persons: Germany's DAX, Eli Lilly, Thali, Narendra Modi, Joe Biden, Biden, Tim Cook, Alphabet's Sundar Pichai, Satya Nadella, Raj Subramaniam, Goldman Sachs, Goldman Organizations: New York Stock Exchange, CNBC, Dice Therapeutics, country's Institute for Public Policy Research, Monetary Fund, U.S, House Locations: New York City, San Francisco, India, China

☆ Wall Street ends lower, pausing rally as Powell testimony looms
▼ + stars: | 2023-06-20 | by ( Stephen Culp | ) www.reuters.com time to read: +4 min

All three major U.S. equity indexes ended the session in the red but off session lows, with oil super-majors Exxon Mobil Corp weighing on the S&P 500 and the Dow. Including Tuesday's loss, the benchmark S&P 500 has advanced 14.3% so far this year. Of the 11 major sectors of the S&P 500 all but consumer discretionary stocks (.SPLRCD) ended in negative territory. The S&P 500 posted 14 new 52-week highs and no new lows; the Nasdaq Composite recorded 68 new highs and 87 new lows. Volume on U.S. exchanges was 11.15 billion shares, compared with the 11.36 billion average for the full session over the last 20 trading days.

Persons: Jerome, Robert Pavlik, Pavlik, We've, Rivian, Morgan Stanley, Daniel Zhang, Eli Lilly, Stephen Culp, Shristi Achar, Shubham Batra, Johann M, Aurora Ellis Organizations: Fedex, Dow, Nasdaq, Federal, Exxon Mobil Corp, Dakota Wealth, U.S . House Financial, Dow Jones, Energy, Rivian Automotive Inc, Tesla Inc, PayPal Holdings, KKR & Co, Nike, Alibaba Group, Adobe Inc, Dice Therapeutics, Fedex Corp, NYSE, Thomson Locations: Fairfield , Connecticut, China, Europe, Bengaluru

☆ S&P 500 ends lower, pausing rally with Powell testimony in view
▼ + stars: | 2023-06-20 | by ( Stephen Culp | ) www.reuters.com time to read: +3 min

Federal Reserve Chairman Jerome Powell's congressional testimony Wednesday looms as a potential market mover. All three major U.S. equity indexes ended the session in the red but off session lows, with oil super-majors Exxon Mobil Corp weighing on the S&P 500 and the Dow. The broad sell-off comes on the heels of the Nasdaq's longest weekly winning streak since March 2019, and the S&P 500's longest since November 2021. As of Friday's close, the benchmark S&P 500 had advanced 20% in the last twelve months, and over 14% so far this year. According to preliminary data, the S&P 500 (.SPX) lost 20.79 points, or 0.47%, to end at 4,388.80 points, while the Nasdaq Composite (.IXIC) lost 22.28 points, or 0.16%, to 13,667.29.

Persons: Jerome, Robert Pavlik, Pavlik, We've, Morgan Stanley, Daniel Zhang, Eli Lilly, Stephen Culp, Shristi Achar, Shubham Batra, Johann M, Aurora Ellis Organizations: Federal, Exxon Mobil Corp, Dow, Dakota Wealth, U.S . House Financial, Nasdaq, Dow Jones, Rivian Automotive Inc, Tesla Inc, Rivian, PayPal Holdings, KKR & Co, Nike, Alibaba, Adobe Inc, Dice Therapeutics, Fedex Corp, Thomson Locations: Fairfield , Connecticut, China, Europe, Bengaluru

Fed Governor Christopher Waller warned on Friday "core inflation is not coming down like I thought it would." Richmond Fed President Thomas Barkin said he was "comfortable" with further rate increases given that inflation was still not on the path back to 2%. Markets now await comments from more Fed officials including Fed Vice Chair Michael Barr later in the day, and Fed Chair Jerome Powell's semiannual monetary policy testimony to the U.S. House Financial Affairs Committee on Wednesday. Adding to the dour mood, China cut its benchmark lending rates by a smaller-than-expected 10 basis points. U.S.-listed shares of Chinese companies including Alibaba Group , JD.com and PDD Holdings (PDD.O) fell between 1% and 6% in premarket trading.

Persons: Eli Lilly, Christopher Waller, Thomas Barkin, CMEGroup's, Waller, Barkin, Michael Barr, Jerome Powell's, Powell, Hogan, Daniel Zhang, Shristi Achar, Shubham Batra, Johann M, Vinay Dwivedi Organizations: Therapeutics, Dow, Nasdaq, Federal Reserve, Richmond Fed, Traders, Microsoft, U.S . House Financial, Housing, Capitol, Riley, Fed, Alibaba, PDD Holdings, Dow e, Adobe Inc, Ford, General Motors, Tesla Inc, Dice Therapeutics, Thomson Locations: China, U.S, Bengaluru

☆ Eli Lilly to buy immunology drug developer Dice for $2.4 billion
▼ + stars: | 2023-06-20 | by ( ) www.reuters.com time to read: +2 min

June 20 (Reuters) - Eli Lilly and Co (LLY.N) agreed to buy Dice Therapeutics Inc (DICE.O) for about $2.4 billion in cash on Tuesday, bolstering its immune disease-related portfolio with a largely oral drug developer. Dice's lead drug DC-806, which is currently in a mid-stage trial, is an immunology drug for a skin condition called psoriasis and other diseases. Indianapolis-headquartered Lilly is focusing on immunology to drive future growth, along with a widely expected approval of obesity drug candidate tirzepatide. Lilly has offered Dice $48 per share in cash, a premium of about 42% to the stock's last close. Lilly's Taltz garnered $2.48 billion in 2022 while its other immunology drug Olumiant generated $830.5 million in sales.

Persons: Eli Lilly, Taltz, Lilly, tirzepatide, Lilly's Taltz, Alex Thompson, Leroy Leo, Khushi, Sriraj Organizations: Dice Therapeutics, U.S . Federal Trade Commission, Pharmaceuticals, Thomson Locations: Indianapolis, Bengaluru

☆ Eli Lilly to acquire Dice Therapeutics for $2.4 billion in autoimmune treatment push
▼ + stars: | 2023-06-20 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Eli Lilly on Tuesday said it struck a $2.4 billion deal to acquire Dice Therapeutics in a bid to bulk up its treatment portfolio for immune-related diseases. Dice Therapeutics' share price jumped more than 37% to just under the purchase price. Auto-immune diseases can causes pain, fatigue, dizziness, depression and rashes, among other symptoms. There are more than 100 known autoimmune diseases, including lupus, rheumatoid arthritis, Crohn's disease and ulcerative colitis. Eli Lilly's immunology portfolio includes drugs like Taltz, which treats plaque psoriasis, and Olumiant, a treatment for rheumatoid arthritis.

Persons: Eli Lilly, Eli Lilly's, Patrik Jonsson, Eli, Taltz Organizations: Dice Therapeutics Locations: Francisco

☆ Stocks making the biggest premarket moves: Alibaba, Dice Therapeutics, Avis and more
▼ + stars: | 2023-06-20 | by ( Michelle Fox | ) www.cnbc.com time to read: +2 min

Atmus Filtration Technologies — Shares of the air filtration company rose more than 2% after a slew of analysts initiated coverage with bullish ratings, including JPMorgan. The bank said Atmus trades at a "deep discounted valuation vs. peers, despite >80% of aftermarket mix, while its planned expansion into industrial filtration should bridge the valuation gap vs. direct filtration peers over time." Avis Budget — Shares added 3.5% in light volume following an upgrade by Morgan Stanley to overweight from equal weight. Philip Morris International — Shares of the tobacco company rose 1.5% in premarket trading after Citi upgraded Philip Morris to buy from neutral. Carnival — Shares moved 1.5% higher in the premarket, building on gains made last week when it was the S&P 500's best performer.

Persons: Daniel Zhang, Eddie Wu, Alibaba's, Eli Lilly, Morgan Stanley, Adam Jonas, Jonas, Avis, Philip Morris, —, Jesse Pound Organizations: Alibaba, Holding, JPMorgan, Avis Budget, Citi, Warner Bros Discovery Locations: Beijing, China, —

☆ Top 10 things to watch in the stock market Tuesday
▼ + stars: | 2023-06-20 | by ( Jeff Marks | ) www.cnbc.com time to read: +3 min

It's a new week but the recent stock market rally makes for a not-so-great set up as Jim Cramer told the Investing Club Monday evening in his weekly column. Jim and "Mad Money" are in Detroit for all things Ford (F) with CEO Jim Farley, covering everything from Ford Blue to Ford Pro to Ford Model e (electric vehicles). Bank of America adds Club stock Amazon (AMZN) to its US 1 list. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Dow, Jim, Jim Farley, They'll, Elon Musk, Sartorius, Cowen, Eli Lilly, Raymond James, Morgan Stanley, Philip Morris, Jim Cramer's Organizations: Nasdaq, Ford, Ford Pro, Ford Model, Elon, Bank of America, Nvidia, Club, Dice Therapeutics, Avis Budget, Citi, Delta Air Lines, DAL, PayPal, Nike, Dow, Barclays, Jim Cramer's Charitable, CNBC Locations: Detroit

Eight of the 11 S&P 500 sub-sectors were in the red, with the energy index (.SPNY) leading declines. U.S. markets ended lower on Friday as comments from Fed officials curtailed optimism that the central bank was nearing the end of its aggressive interest rate hikes. Traders now see a 72% chance of Fed hiking its key benchmark rates by 25 basis points in July, according to CMEGroup's Fedwatch Tool. Declining issues outnumbered advancers for a 2.43-to-1 ratio on the NYSE and a 1.82-to-1 ratio on the Nasdaq. The S&P index recorded 11 new 52-week highs and no new low, while the Nasdaq recorded 38 new highs and 40 new lows.

Persons: Eli Lilly, Tesla, Rivian, homebuilding, Sam Stovall, CMEGroup's, Michael Barr, Jerome Powell's, Morgan Stanley, Daniel Zhang, advancers, Shristi Achar, Shubham Batra, Johann M, Vinay Dwivedi, Shounak Organizations: Therapeutics, Nike, Dow, Nasdaq, U.S . Federal Reserve, CFRA Research, Tesla Inc, Reuters, EV, U.S . House Financial, PayPal Holdings, KKR & Co, Alibaba, PDD Holdings, Dow Jones, Adobe Inc, Dice Therapeutics, NYSE, Thomson Locations: U.S, Europe, China, Bengaluru

☆ Stocks making the biggest moves midday: Goldman Sachs, Avis, Rivian, Nike and more
▼ + stars: | 2023-06-20 | by ( Brian Evans | ) www.cnbc.com time to read: +2 min

Check out the companies making headlines in midday trading. Goldman Sachs — Shares declined 2.2% in midday trading. Avis — The car rental company surged more than 6%. Chevron , ExxonMobil — Energy giants Chevron and ExxonMobil slipped more than 2% each in midday trading. Dice Therapeutics — Shares surged 37% after Eli Lilly said it was acquiring the biopharmaceutical company for $2.4 billion.

Persons: Goldman Sachs, Avis —, Morgan Stanley, Avis, Jay Sole, Rivian, Eli Lilly, Alibaba, Daniel Zhang, Wells, Biden, —, Jesse Pound, Alex Harring, Michelle Fox Theobald Organizations: UBS, Bank of America, Chevron, ExxonMobil — Energy, ExxonMobil, U.S . West Texas, Nike —, Rivian, Ford, GM, Intel, Bloomberg, Wall, JPMorgan Chase Locations: China, Brent, U.S, Germany, Wells Fargo, New York City

☆ Cramer's lightning round: Wait for Texas Roadhouse to come down
▼ + stars: | 2022-10-17 | by ( Krystal Hur | ) www.cnbc.com time to read: 1 min

I like profitable companies with good balance sheets. Loading chart...Veru Inc : "A lot of people bet against it, so it could be a very binary, up big, down big situation." Loading chart...Texas Roadhouse Inc : "We have to wait for that one to come down, because it's had too big a move." Loading chart...Organon & Co : "We are going to find out what this story is, and then we're going to come back to you." Dice Therapeutics Inc : "I can not recommend it, particularly because the company is losing money hand over fist."

Search resuls for: "Dice Therapeutics"

16 mentions found